99 related articles for article (PubMed ID: 16053917)
1. Separation of bisdioxopiperazine- and vanadate resistance in topoisomerase II.
Sorensen TK; Grauslund M; Jensen PB; Sehested M; Jensen LH
Biochem Biophys Res Commun; 2005 Sep; 334(3):853-60. PubMed ID: 16053917
[TBL] [Abstract][Full Text] [Related]
2. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
3. Stability of the topoisomerase II closed clamp conformation may influence DNA-stimulated ATP hydrolysis.
Vaughn J; Huang S; Wessel I; Sorensen TK; Hsieh T; Jensen LH; Jensen PB; Sehested M; Nitiss JL
J Biol Chem; 2005 Mar; 280(12):11920-9. PubMed ID: 15647268
[TBL] [Abstract][Full Text] [Related]
4. A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase IIalpha in vivo.
Grauslund M; Thougaard AV; Füchtbauer A; Hofland KF; Hjorth PH; Jensen PB; Sehested M; Füchtbauer EM; Jensen LH
Mol Pharmacol; 2007 Oct; 72(4):1003-14. PubMed ID: 17622580
[TBL] [Abstract][Full Text] [Related]
5. Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance.
Renodon-Cornière A; Jensen LH; Nitiss JL; Jensen PB; Sehested M
Biochemistry; 2003 Aug; 42(32):9749-54. PubMed ID: 12911317
[TBL] [Abstract][Full Text] [Related]
6. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB
Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287
[TBL] [Abstract][Full Text] [Related]
7. Salvicine functions as novel topoisomerase II poison by binding to ATP pocket.
Hu CX; Zuo ZL; Xiong B; Ma JG; Geng MY; Lin LP; Jiang HL; Ding J
Mol Pharmacol; 2006 Nov; 70(5):1593-601. PubMed ID: 16914642
[TBL] [Abstract][Full Text] [Related]
8. The QTK loop is essential for the communication between the N-terminal atpase domain and the central cleavage--ligation region in human topoisomerase IIalpha.
Bendsen S; Oestergaard VH; Skouboe C; Brinch M; Knudsen BR; Andersen AH
Biochemistry; 2009 Jul; 48(27):6508-15. PubMed ID: 19485418
[TBL] [Abstract][Full Text] [Related]
9. Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha.
Patel S; Jazrawi E; Creighton AM; Austin CA; Fisher LM
Mol Pharmacol; 2000 Sep; 58(3):560-8. PubMed ID: 10953049
[TBL] [Abstract][Full Text] [Related]
10. Probing the role of linker substituents in bisdioxopiperazine analogs for activity against wild-type and mutant human topoisomerase II alpha.
Renodon-Cornière A; Sørensen TK; Jensen PB; Nitiss JL; Søkilde B; Sehested M; Jensen LH
Mol Pharmacol; 2003 May; 63(5):1159-68. PubMed ID: 12695544
[TBL] [Abstract][Full Text] [Related]
11. Self-association and DNA binding properties of the human topoisomerase IIA alpha2HTH module.
Morant-Lhomel A; René B; Zargarian L; Troalen F; Mauffret O; Fermandjian S
Biochimie; 2006; 88(3-4):253-63. PubMed ID: 16213649
[TBL] [Abstract][Full Text] [Related]
12. Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors.
Jensen LH; Thougaard AV; Grauslund M; Søkilde B; Carstensen EV; Dvinge HK; Scudiero DA; Jensen PB; Shoemaker RH; Sehested M
Cancer Res; 2005 Aug; 65(16):7470-7. PubMed ID: 16103101
[TBL] [Abstract][Full Text] [Related]
13. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
[TBL] [Abstract][Full Text] [Related]
14. NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors.
Onda T; Toyoda E; Miyazaki O; Seno C; Kagaya S; Okamoto K; Nishikawa K
Cancer Lett; 2008 Jan; 259(1):99-110. PubMed ID: 17998154
[TBL] [Abstract][Full Text] [Related]
15. A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.
Liang H; Wu X; Yalowich JC; Hasinoff BB
Mol Pharmacol; 2008 Mar; 73(3):686-96. PubMed ID: 18045852
[TBL] [Abstract][Full Text] [Related]
16. The ATP-operated clamp of human DNA topoisomerase IIalpha: hyperstimulation of ATPase by "piggy-back" binding.
Campbell S; Maxwell A
J Mol Biol; 2002 Jul; 320(2):171-88. PubMed ID: 12079377
[TBL] [Abstract][Full Text] [Related]
17. Interaction of human DNA topoisomerase II alpha with DNA: quantification by surface plasmon resonance.
Renodon-Cornière A; Jensen LH; Nitiss JL; Jensen PB; Sehested M
Biochemistry; 2002 Nov; 41(45):13395-402. PubMed ID: 12416984
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action of ferrocene derivatives on the catalytic activity of topoisomerase IIalpha and beta--distinct mode of action of two derivatives.
Sai Krishna AD; Panda G; Kondapi AK
Arch Biochem Biophys; 2005 Jun; 438(2):206-16. PubMed ID: 15907782
[TBL] [Abstract][Full Text] [Related]
19. N-terminal and core-domain random mutations in human topoisomerase II alpha conferring bisdioxopiperazine resistance.
Jensen LH; Wessel I; Møller M; Nitiss JL; Sehested M; Jensen PB
FEBS Lett; 2000 Sep; 480(2-3):201-7. PubMed ID: 11034329
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors.
Jiménez-Alonso S; Orellana HC; Estévez-Braun A; Ravelo AG; Pérez-Sacau E; Machín F
J Med Chem; 2008 Nov; 51(21):6761-72. PubMed ID: 18816045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
